Will Pfizer again attempt to acquire Allergan?

[anonymous]

When providing the outlook for 2018, Saunders said that Allergan faces LOE losses in 2018. But still it has got good long-term prospects. Saunders says that current stock price doesn't reflect Allergan's true value. Wall Street gives thumbs up to his speech.

 

[anonymous]

https://seekingalpha.com/amp/article/4135949-pfizer-make-second-attempt-acquire-allergan

 

[anonymous]

https://seekingalpha.com/amp/article/4135949-pfizer-make-second-attempt-acquire-allergan

If what you read on here is “true” about the layoffs to r&d and Irvine this looks like it will be a done deal.

 

[anonymous]

Let's see here:

Saunders packages up the Actavis generic division with a nice, big red bow and sells it to Teva. Teva nearly goes bankrupt and the dog of a division drags down AGN stock for over a year.

Bill-of-goods.

Next, Saunders packages up FRX, ACT, and AGN into one messy conglomerate, puts some polish and fresh smiles out front and dangles "inversion deal" to PFE for around $350 / share.

PFE stockholders should get on their knees and thank that jackass Jack Lew in the Treasury Department for squandering the deal. If you look at the resulting mess that this frankenstein-mashup of three formerly quality companies have transmogrified into -- and look at the current performance, stock price, portfolio, and talent level?

Bill-of-goods.

Esmya is going to be a very limited-use product (if it makes it to market.) Rapastinel will be just another antidepressant, except administered with a needle (which Psychiatrists hate.) It will have no "immediate effect." That's the realm of Roche with their nasally-administered esketamine.

Slick Saunders has reached the end of his dog and pony show. If he manages to unload this dumpster fire onto PFE even at the current stock price he'll be doing all existing stockholders of AGN his final good deed.

 

[anonymous]

Since Trump reduced the corporate tax rate Pfizer doesn't want Allergan, I could see Pfizer Mayberry buying up some of the Derm products to boost their Derm portfolio but that's a stretch also.